Nantes
France
9
2024-07-11
6
2023-07-11
These are the the leading inventors for applications assigned to OGD2 PHARMA:
OGD2 PHARMA based in Nantes, FR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
NEW METHOD TO IMPROVE NK CELLS CYTOTOXICITY
#2 | 2024-06-13NEW METHOD TO IMPROVE THE ANTI-TUMORAL ACTIVITY OF MACROPHAGES
#3 | 2024-05-02USE OF CASD1 AS A BIOMARKER OF A CANCER EXPRESSING THE O-ACETYLATED-GD2 GANGLIOSIDE
#4 | 2019-12-12 ✅ Patent 11,697,689 granted on 2023-07-11Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
#5 | 2019-08-01 ✅ Patent 11,440,968 granted on 2022-09-13Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2)
#6 | 2019-01-24 ✅ Patent 10,745,489 granted on 2020-08-18Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer
#7 | 2016-09-29 ✅ Patent 10,669,328 granted on 2020-06-02Human IgG1 derived antibody with pro-apoptotic activity
#8 | 2016-09-22 ✅ Patent 10,611,848 granted on 2020-04-07Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
#9 | 2016-03-10 ✅ Patent 10,000,575 granted on 2018-06-19Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
Also check out OGD2 PHARMA's (Nantes, France) applicant profile with 9 patent applications submitted.
151591 ⎘